Cargando…

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India

BACKGROUND: Breast cancer is the leading cause of cancer among women in India. Treatment with hormone therapy reduces recurrence. We undertook this cost-effectiveness study to ascertain the treatment option offering the best value for money. METHODS: The lifetime costs and health outcomes of using t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butani, Dimple, Gupta, Nidhi, Jyani, Gaurav, Bahuguna, Pankaj, Kapoor, Rakesh, Prinja, Shankar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636459/ https://www.ncbi.nlm.nih.gov/pubmed/34866937 http://dx.doi.org/10.2147/BCTT.S331831

Ejemplares similares

Cost-effectiveness analysis of ‘test and treat’ policy for antiretroviral therapy among heterosexual HIV population in India
por: Singh, Malkeet, et al.
Publicado: (2022)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Stick or switch? Audit of the use of switch therapy from tamoxifen to an aromatase inhibitor in breast cancer
por: Weeraman, S, et al.
Publicado: (2010)

Peritoneal dialysis–first initiative in India: a cost-effectiveness analysis
por: Gupta, Dharna, et al.
Publicado: (2021)

Cost-Effectiveness of Temozolamide for Treatment of Glioblastoma Multiforme in India
por: Gupta, Nidhi, et al.
Publicado: (2021)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
por: Göbel, Andy, et al.
Publicado: (2019)

Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions
por: Ligibel, Jennifer A, et al.
Publicado: (2005)

Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy
por: Derzko, C., et al.
Publicado: (2007)

Health related quality of life among Rheumatic Fever and Rheumatic Heart Disease patients in India
por: Dixit, Jyoti, et al.
Publicado: (2021)

Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
por: Uchino, J., et al.
Publicado: (1994)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
por: Cuzick, J, et al.
Publicado: (2006)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial
por: Tjan-Heijnen, Vivianne C.G., et al.
Publicado: (2023)

Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer
por: Güth, U, et al.
Publicado: (2008)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984)

Economic Analysis of Delivering Postpartum Intrauterine Contraceptive Device Services in India
por: Bahuguna, Pankaj, et al.
Publicado: (2019)

Cost effectiveness of strategies for cervical cancer prevention in India
por: Chauhan, Akashdeep Singh, et al.
Publicado: (2020)

Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy
por: Pedersini, Rebecca, et al.
Publicado: (2022)

Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013)

Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
por: Chen, Han, et al.
Publicado: (2020)

Drug prescription behavior: A cross-sectional study in public health facilities in two states of North India
por: Tripathy, Jaya Prasad, et al.
Publicado: (2018)

India’s publicly financed insurance scheme: scope for revision – authors’ reply
por: Prinja, Shankar, et al.
Publicado: (2023)

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
por: Francini, G, et al.
Publicado: (2006)

Precautions for Patients Taking Tamoxifen or Aromatase Inhibitors
por: Heery, Mary
Publicado: (2023)

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
por: Ellis, Matthew J., et al.
Publicado: (2008)

Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy
por: Pedersini, Rebecca, et al.
Publicado: (2019)

Predicting the Benefit of Adjuvant Aromatase Inhibitor Therapy in Postmenopausal Breast Cancer Patients with Phosphorylated S6K1 Expression Status
por: Choi, Jihye, et al.
Publicado: (2019)

Are another 5 years of adjuvant aromatase inhibitor therapy needed?
por: Mo, Qin-Guo, et al.
Publicado: (2016)

Cost analysis of implementing mHealth intervention for maternal, newborn & child health care through community health workers: assessment of ReMIND program in Uttar Pradesh, India
por: Prinja, Shankar, et al.
Publicado: (2018)

COVID-19 management: The vaccination drive in India
por: Purohit, Neha, et al.
Publicado: (2022)

Financing Comprehensive Immunization Services in Lao PDR: A Fiscal Space Analysis From a Public Policy Perspective
por: Bahuguna, Pankaj, et al.
Publicado: (2022)

Coverage and Financial Risk Protection for Institutional Delivery: How Universal Is Provision of Maternal Health Care in India?
por: Prinja, Shankar, et al.
Publicado: (2015)

Cutaneous sarcoidosis possibly associated with aromatase inhibitors and tamoxifen
por: Sawada, Tomoya, et al.
Publicado: (2023)

Health-related quality of life among Indian population: The EQ-5D population norms for India
por: Jyani, Gaurav, et al.
Publicado: (2023)

Availability of medicines in public sector health facilities of two North Indian States
por: Prinja, Shankar, et al.
Publicado: (2015)

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials
por: Ferretti, G, et al.
Publicado: (2006)

Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis
por: Lee, Young-Kyun, et al.
Publicado: (2020)

Role of insurance in determining utilization of healthcare and financial risk protection in India
por: Prinja, Shankar, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jj5nppahk4odsimgeibvt50efd